Navigation Links
BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

- First in human clinical data highlight safety profile of BSI-201 in

subjects with advanced solid tumors -

BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data supporting its lead PARP inhibitor, BSI-201, will be presented at the 2008 American Society of Clinical Oncology annual meeting in Chicago.

Findings will be presented from the first in human Phase 1 study of BSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as a monotherapy in subjects with advanced solid tumors. BiPar will also present a Phase 1b study evaluating BSI-201 in combination with topotecan, gemcitabine, temozolomide and carboplatin/paclitaxel in subjects with advanced solid tumors. The primary objective of these respective studies is to assess the safety profile of BSI-201 when used as a monotherapy and in combination with cytotoxic chemotherapy in subjects with measurable disease.

The schedule of poster presentations is as follows:

Title: First in Human Phase 1 Study of BSI-201, a Small Molecule

Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with

Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract#: 3577

Title: A Phase 1B Study Evaluating BSI-201 in Combination with

Chemotherapy in Subjects with Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract #: 3579

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
6. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)...   , Total ... Consumable Sales  Clinical sales grow 16% year-over-year  ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... first quarter ended March 31, 2016 and provided an ... commercial strategy. First Quarter 2016 Revenue Results ...
(Date:4/27/2016)... April 27, 2016   Zillion Group ... health technology platform, which specializes in live video ... scalable digital products, Zillion enables companies to realize ... consumers to take control of their health. ... conferencing – including one-to-one, group and webcast scheduled ...
(Date:4/27/2016)... LEXINGTON, Massachusetts , April 27, 2016 ... announces that Jeff Poulton , Chief Financial Officer, will ... in Boston, MA on Wednesday, May ... live audio webcast will be available on the Presentations and ... Subsequently, a replay of the webcast will be available on ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, ... ... integrated manufacturer and engineer of patented products, announces the Gyrociser, an exercise invention ... industry is worth $2 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
(Date:4/29/2016)... ... ... York City based oral and maxillofacial surgeon Dr. Majid Jamali is an expert ... sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients who suffer ... jaw bones. This surgery is performed to correct the alignment of the jaw. It is ...
(Date:4/29/2016)... OR (PRWEB) , ... April 29, 2016 , ... For ... dinner as the meal to miss. That was among the many new lifestyle diet ... on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence ...
Breaking Medicine News(10 mins):